Synthetic lipoprotein as nano-material vehicle in the targeted drug delivery

References

• Berkel TJCV, Fluiter K, Nion S, Kruyt JK. (1999). The role of scavenger-receptor class a and b in the metabolism of modified LDL and HDL. Atherosclerosis 144:83.
   Web of Science ®Google Scholar
• Brodeur MR, Brissette L, Falstrault L, et al. (2008). Scavenger receptor of class b expressed by osteoblastic cells are implicated in the uptake of cholesteryl ester and estradiol from ldl and hdl3. J Bone Miner Res 23:326–37.
   PubMed Web of Science ®Google Scholar
• Chen Q, Watson JT, Marengo SR, et al. (2006). Gene expression in the lncap human prostate cancer progression model: progression associated expression in vitro corresponds to expression changes associated with prostate cancer progression in vivo. Cancer Lett 244:274–88.
   PubMed Web of Science ®Google Scholar
• Corbin IR. (2013). Ligand-coupled lipoprotein for ovarian cancer-specific drug delivery. Methods Mol Biol 1049:467–80.
   PubMedGoogle Scholar
• Counsell R, Longino MA, Weichert JP. (2009). Blood-pool carrier for lipophilic imaging agents. US: US 7582279 B2.
   Google Scholar
• Crosby NM, Ghosh M, Su B, et al. (2015). Anti-CD20 single chain variable antibody fragment-apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas. Biochem Cell Biol 93:343–50.
   PubMed Web of Science ®Google Scholar
• Emami J, Rezazadeh M, Varshosaz J, et al. (2012). Formulation of LDL targeted nanostructured lipid carriers loaded with paclitaxel: a detailed study of preparation, freeze drying condition, and in vitro cytotoxicity. J Nanomater 2012:3–12.
   Web of Science ®Google Scholar
• Garai A, Kumar M, Sinha W, et al. (2014). Synthesis, electron transport, and charge storage properties of fullerene–zinc porphyrin hybrid nanodiscs. RSC Advances 4:138–42.
   Google Scholar
• Hammel M, Laggner P, Prassl R. (2003). Structural characterisation of nucleoside loaded low density lipoprotein as a main criterion for the applicability as drug delivery system. Chem Phys Lipids 123:193–207.
   PubMed Web of Science ®Google Scholar
• Hayavi S, Halbert GW. (2005). Synthetic low-density lipoprotein, a novel biomimetic lipid supplement for serum-free tissue culture. Biotechnol Prog 21:1262–8.
   PubMed Web of Science ®Google Scholar
• Hinze CL. (2013). Optimization of reconstituted high density lipoprotein nanoparticles as a delivery system for neuroblastoma treatment [Dissertations & Theses]. Gradworks. Fort Worth (TX): University of North Texas Health Science Center. 56 p.
   Google Scholar
• Huynh NT, Passirani C, Saulnier P, Benoit JP. (2009). Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 379:201–9.
   PubMed Web of Science ®Google Scholar
• Jori G, Reddi E. (1993). The role of lipoproteins in the delivery of tumour-targeting photosensitizers. Int J Biochem 25:1369–75.
   PubMedGoogle Scholar
• Kanwar RK, Chaudhary R, Tsuzuki T, Kanwar JR. (2012). Emerging engineered magnetic nanoparticulate probes for targeted MRI of atherosclerotic plaque macrophages. Nanomedicine 7:735–49.
   PubMed Web of Science ®Google Scholar
• Khumsupan P, Ramirez R, Khumsupan D, Narayanaswami V. (2011). Apolipoprotein E LDL receptor-binding domain-containing high-density lipoprotein: a nanovehicle to transport curcumin, an antioxidant and anti-amyloid bioflavonoid. Biochim Biophys Acta 1808:352–9.
   PubMed Web of Science ®Google Scholar
• Kim SI, Shin D, Choi TH, et al. (2007). Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther 15:1145–52.
   PubMed Web of Science ®Google Scholar
• Kim HR, Kim IK, Bae KH, et al. (2008). Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol Pharm 5:622–31.
   PubMed Web of Science ®Google Scholar
• Lacko AG, Mcconathy WJ. (2009). Targeted cancer chemotherapy using synthetic nanoparticles. US 20090110739 A1.
   Google Scholar
• Lavasanifar A, Samuel J, Kwon GS. (2000). Micelles of poly(ethylene oxide)-block-poly(N-alkyl stearate L-aspartamide): synthetic analogues of lipoproteins for drug delivery. J Biomed Mater Res 52:831–5.
   PubMed Web of Science ®Google Scholar
• Li H, Marotta DE, Kim S, et al. (2005). High payload delivery of optical imaging and photodynamic therapy agents to tumors using phthalocyanine-reconstituted low-density lipoprotein nanoparticles. J Biomed Opt 10:41203.
   PubMed Web of Science ®Google Scholar
• Lin Q, Chen J, Jin H, et al. (2012). Efficient systemic delivery of sirna by using high-density lipoprotein-mimicking peptide lipid nanoparticles. Nanomedicine 7:1813–25.
   PubMed Web of Science ®Google Scholar
• Lin Q, Chen J, Zhang Z, Zheng G. (2012). Study on the cytosolic delivery mechanism of HDL-mimicking Peptide-Phospholipid Scaffold (HPPS) By confocal microscopy. Biomedical Optics and 3-D Imaging, OSA Technical Digest. Opt Soc Am 2012:BSu3A.12.
   Google Scholar
• Lin Q, Jin CS, Huang H, et al. (2014). Nanoparticle-enabled, image-guided treatment planning of target specific rnai therapeutics in an orthotopic prostate cancer model. Small 10:3072–82.
   PubMed Web of Science ®Google Scholar
• Lin Q, Qian Y, Zhang Z. (2016). CT/FMT dual-model imaging of breast cancer based on peptide-lipid nanoparticles. SPIE Proc 9709:97090S.
   Google Scholar
• Masquelier M, Ros M, Peterson C, et al. (1989). Method for the production of a macromolecular carrier loaded with a biologically active substance. US, 4868158.
   Google Scholar
• McConathy WJ, Nair MP, Paranjape S, et al. (2008). Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 19:183–8.
   PubMed Web of Science ®Google Scholar
• Nam DE, Kim OK, Park YK, Lee J. (2016). Synthetic high-density lipoprotein-like nanocarrier improved cellular transport of lysosomal cholesterol in human sterol carrier protein-deficient fibroblasts. J Med Food 19:62–7.
   PubMed Web of Science ®Google Scholar
• Nanjee MN, Miller NE. (1989). Human hepatic low-density lipoprotein receptors: associations of receptor activities in vitro with plasma lipid and apolipoprotein concentrations in vivo. Biochim Biophys Acta 1002:245–55.
   PubMedGoogle Scholar
• Navab M, Reddy ST, Meriwether D, et al. (2015). ApoA-I mimetic peptides: a review of the present status. Apolipoprotein mimetics in the management of human disease. New York: Springer International Publishing.
   Google Scholar
• Ng KK, Lovell JF, Zheng G. (2011). Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res 44:1105–13.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Blakely EA, Bjornstad KA, et al. (2007). Synthetic nano-low density lipoprotein as targeted drug delivery vehicle for glioblastoma multiforme. Int J Pharm 328:86–94.
   PubMed Web of Science ®Google Scholar
• Nikanjam M, Gibbs AR, Hunt CA, et al. (2007). Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme. J Control Release 124:163–71.
   PubMed Web of Science ®Google Scholar
• Oluwadara O, Chiappelli F. (2009). Biomarkers for early detection of high risk cancers: from gliomas to nasopharyngeal carcinoma. Bioinformation 3:332–9.
   PubMedGoogle Scholar
• Rensen PC, de Vrueh RL, Kuiper J, et al. (2001). Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. Adv Drug Deliv Rev 47:251–76.
   PubMed Web of Science ®Google Scholar
• Rui M, Tang H, Li Y, et al. (2013). Recombinant high density lipoprotein nanoparticles for target-specific delivery of siRNA. Pharm Res 30:1203–14.
   PubMed Web of Science ®Google Scholar
• Samadi-Baboli M, Favre G, Bernadou J, et al. (1990). Comparative study of the incorporation of ellipticine-esters into low density lipoprotein (LDL) and selective cell uptake of drug-LDL complex via the LDL receptor pathway in vitro. Biochem Pharmacol 40:203–12.
   PubMed Web of Science ®Google Scholar
• Shah S, Chib R, Raut S, et al. (2016). Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent. J Photochem Photobiol B 155:60–5.
   PubMed Web of Science ®Google Scholar
• Shaw JM, Shaw KV. (1991). Key issues in the delivery of pharmacological agents using lipoproteins: design of a synthetic apoprotein-lipid carrier. Targeted Diagn Ther 5:351–83.
   PubMedGoogle Scholar
• Shin JY, Yang Y, Heo P, et al. (2012). pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy. Int J Nanomedicine 7:2805–16.
   PubMed Web of Science ®Google Scholar
• Simonsen JB. (2016). Evaluation of reconstituted high-density lipoprotein (rHDL) as a drug delivery platform - a detailed survey of rHDL particles ranging from biophysical properties to clinical implications. Nanomedicine 12:2161–79.
   PubMed Web of Science ®Google Scholar
• Singh S. (2013). Nanomaterials as non-viral siRNA delivery agents for cancer therapy. Bioimpacts 3:53–65.
   PubMedGoogle Scholar
• Song Q, Song H, Xu J, et al. (2016). Biomimetic ApoE-reconstituted high density lipoprotein nanocarrier for blood-brain barrier penetration and amyloid beta-targeting drug delivery. Mol Pharm 13:3976–87.
   PubMed Web of Science ®Google Scholar
• Su HT, Li X, Liang DS, Qi XR. (2016). Synthetic low-density lipoprotein (sLDL) selectively delivers paclitaxel to tumor with low systemic toxicity. Oncotarget 7:51535–52.
   PubMed Web of Science ®Google Scholar
• Van Berkel TJ, Van EM, Herijgers N, et al. (2000). Scavenger receptor classes a and b. their roles in atherogenesis and the metabolism of modified LDL and HDL. Ann N Y Acad Sci 902:113–27.
   PubMed Web of Science ®Google Scholar
• Vassiliou G, Mcpherson R. (2004). A novel efflux-recapture process underlies the mechanism of high-density lipoprotein cholesteryl ester-selective uptake mediated by the low-density lipoprotein receptor-related protein. Arterioscler Thromb Vasc Biol 24:1669–75.
   PubMed Web of Science ®Google Scholar
• Versluis AJ, Rump ET, Rensen PC, et al. (1999). Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo. J Pharmacol Exp Ther 289:1–7.
   PubMed Web of Science ®Google Scholar
• Xu Y, Jin X, Ping Q, et al. (2010). A novel lipoprotein-mimic nanocarrier composed of the modified protein and lipid for tumor cell targeting delivery. J Control Release 146:299–308.
   PubMed Web of Science ®Google Scholar
• Yang S, Damiano MG, Zhang H, et al. (2012). Biomimetic synthetic high density lipoprotein nanostructures target the SR-B1 receptor and differentially manipulate cellular cholesterol flux in lymphoma cells: a novel treatment paradigm. Blood 120:157.
   Web of Science ®Google Scholar
• Yuan Y, Wen J, Tang J, et al. (2016). Synthetic high-density lipoproteins for delivery of 10-hydroxycamptothecin. Int J Nanomedicine 11:6229–38.
   PubMed Web of Science ®Google Scholar
• Zhou P, Hatziieremia S, Elliott MA, et al. (2010). Uptake of synthetic Low Density Lipoprotein by leukemic stem cells-a potential stem cell targeted drug delivery strategy. J Control Release 148:380–7.
   PubMed Web of Science ®Google Scholar